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Live attenuated inﬂuenza vaccines (LAIV) can prevent inﬂuenza illness and death in children. The absence of known
correlates of protection induced by LAIV requires human studies of underlying mechanisms of vaccine-induced
immunity, to further elucidate the immunological processes occurring. In this study, children scheduled for elective
tonsillectomy were enrolled in a clinical trial to evaluate the immune response to LAIV, in order to compare T and B cell
gene expression proﬁles. Twenty-three children (aged 3–17 years) were divided into 4 groups; unvaccinated controls, or
vaccinated intranasally with LAIV at days 3–4, 6–7, and 12–15 before tonsillectomy. Total RNA extraction was performed
on tonsillar tissue and high RNA quality was assured. The samples were then analyzed using a validated RT2 Proﬁler PCR
Array containing 84 gene-speciﬁc primers involved in B and T cell activation, proliferation, differentiation, regulation and
polarization. The gene expression after LAIV vaccination was subsequently compared to the controls. We observed that
at d 3–4 post vaccination, 6 genes were down-regulated, namely APC, CD3G, FASLG, IL7, CD8A and TLR1. Meanwhile at
6–7 days post vaccination, 9 genes were signiﬁcantly up-regulated, including RIPK2, TGFB1, MICB, SOCS1, IL2RA, MS4A1,
PTPRC, IL2 and IL8. By days 12–15 the genes RIPK2, IL4, IL12B and TLR2 were overexpressed. RIPK2 was upregulated at all
3 time points. Our data suggests an overall proliferation, differentiation and regulation of B and T cells in the tonsils
following LAIV, where the majority of genes were up-regulated at days 6–7 and normalized by days 12–15. These
ﬁndings may provide a ﬁrst step into deﬁning future biomarkers or correlates of protection after LAIV immunization.
Introduction
The burden of global influenza epidemics is 3 to 5 million
cases of severe illness and with estimated 250,000 to 500,000
deaths annually.1-3 Since seasonal influenza can be prevented by
vaccination, the World Health Organization (WHO) recom-
mends annual vaccination of individuals at increased risk of the
complications of influenza.4-7 Particularly, young children under
the age of 2 are a major source of viral transmission,8 with the
highest morbidity and mortality observed in older patients
(>65 years old). Thus, the vaccination of young healthy children
may reduce the levels of transmission in society.
Recently, the Live Attenuated Influenza Vaccine (LAIV) has
been licensed in Europe for children.9-11 LAIV is administered
intranasally at the portal of entry of the virus, thereby inducing
local immune responses in the draining lymph nodes and ton-
sils,12,13 in turn leading to B and T cell activation.14,15 Despite
lower levels of serum haemagglutination inhibition (HI) anti-
body titres elicited by LAIV compared to the inactivated trivalent
influenza vaccine (inactivated TIV), it has been shown to provide
effective immunity in children, measured by reduction in virus
survival and replication.16,17 LAIV has therefore been incorpo-
rated into childhood vaccination programs in several countries,
including USA, Canada, and several European countries.18 Inter-
estingly, one of the limitations to widespread inclusion of LAIV
into national vaccination programs includes the lack of good cor-
relate of protection.19 Therefore, there is a need to further char-
acterize and understand the underlying immunological
mechanisms of action of LAIV in order to possibly find a reliable
correlate of protection in the future.
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Given our current understanding of LAIV and its ability to
induce effective humoral and cell mediated immune responses in
children, we aimed to investigate the dynamics of the locally
induced B and T cell gene expression profiles in the tonsils follow-
ing LAIV vaccination.20 Our results indicate an overall prolifera-
tion, differentiation and regulation of B and T cells in the tonsils
following LAIV, where dynamic changes in gene expression levels
were identified. In particular RIPK2, IL-2 and IL-2RA were found
to be highly upregulated. These findings are important starting
points for unravelling the immunological processes that occur in
the upper respiratory tract after LAIV immunization.
Material and Methods
Study population and experimental setup
Twenty-three children aged 3–17 years old and scheduled for
tonsillectomy at the Department of Otorhinolaryngology, Hau-
keland University Hospital, Bergen, Norway were recruited for
this study. A detailed explanation of the study prospective and
protocols were explained to the recruited subjects and guardians
upon enrolment. Written informed consent was obtained from
patients and their guardians. The demographics of the subjects
included in this study are presented in Table 1. The Regional
Ethics Committee, and Norwegian Medicines Agency approved
this study (EUDRACT # 2012-00284824 and www.clinical-
trials.gov NCT01866540).
Vaccine strains
LAIV (FluenzTM MedImmune LLC, USA), for 2012–13, is a
seasonal trivalent influenza vaccine administered intranasally.
The vaccine contained A/California/07/2009 (H1N1) pdm09-
like strain, A/Victoria/361/2011 (H3N2)-like strain, and B/Mas-
sachusetts/2/2012-like strain.
Haemagglutination inhibition (HI) assay
Serum samples collected prior to vaccination and at tonsillec-
tomy were tested by the HI assay. Serial dilutions of serum sam-
ples, 8 Hemagglutinating units of the homologous H1N1 and
H3N2 vaccine strains and 0.7% turkey red blood cells were
employed to measure the serum HI titers following standard
procedure.21,22
Tonsil tissue preparation and RNA isolation
A sectioned palatine tonsil (2£ 10 £ 10 mm) was submerged
in PAXgene Blood RNA Tube reagent (PAXgene Blood RNA
kit, PreAnalytiX GmbH, Hombrecht, Germany), in order to sta-
bilize intracellular RNA by inhibiting Ribonuclease (RNase)
activity and preserve ex-vivo gene expression. Lysing matrix D
(MP Biomedicals, Santa Ana, California, USA) and small
ceramic beads were added to the tissue and shaken for 30 seconds
before storage at ¡20C. Total RNA isolation was performed
using the PAXgene Tissue RNA kit (PreAnalytiX GmbH, Hom-
brecht, Germany), according to the manufacturer’s instructions.
Total RNA quality control
The quantity, purity and integrity of the total RNA was mea-
sured using with the Nanodrop ND1000 (Thermo Fisher) and
the Agilent Bioanalyzer, using the Agilent RNA 6000 Nano
Chip (Cat. no. 5067-1511, Agilent Technologies, USA) and the
Agilent RNA 6000 Pico (Cat no. 5067-1513, Agilent Technolo-
gies, USA).
Table 1. Demographics of patients included in the study
Patient
no. Group*
Tonsillectomy
days post-
vaccination
Age
(years) Gender# Hypertrophy
Recurrent
tonsillitis
1 Control 0 5 M Yes No
2 Control 0 3 M No Yes
3 Control 0 3 F No Yes
4 Control 0 6 M Yes Yes
5 Control 0 6 F Yes No
6 Control 0 6 M Yes No
7 1 3 14 M Yes Yes
8 1 3 4.5 M Yes No
9 1 3 3 M Yes No
10 1 4 3.5 F Yes Yes
11 1 4 3.5 F Yes No
12 2 6 3 M Yes No
13 2 6 16 F Yes No
14 2 7 5 M No Yes
15 2 7 4 M Yes No
16 2 7 6 M Yes Yes
17 2 7 3 M Yes Yes
18 3 12 3.5 F Yes No
19 3 13 3.5 M Yes Yes
20 3 14 17 F Yes No
21 3 14 3.5 F Yes Yes
22 3 14 4 M Yes Yes
23 3 15 10 F Yes Yes
*Our study population was divided into 4 groups: unvaccinated (Controls),
tonsillectomy at days 3–4 (Group 1), 6–7 (Group 2), and 12–15 (Group 3)
post vaccination.
#M DMale; F D Female.
Figure 1. Serum hemagglutination inhibition (HI) antibody against the
H1N1 and H3N2 vaccine viruses.
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RT2 profiler PCR array analysis
Total RNA was transcribed into
cDNA (cDNA) using the RT2 SYBR
Green Mastermix and First strand cDNA
kits (Cat. no. PAHS-0532, RT2 Profiler
PCR Array Kit, Qiagen Sciences, Hilden,
Germany). This was followed by cDNA
amplification and quantification as rec-
ommended by the manufacturer.23,24
This validated kit contains internal con-
trols of validation (see Table S1 for full
list of genes). The Cycle threshold (Ct)
values were generated individually, for
each subject and target gene, using the
real-time PCR software Roche LC480 II
(www.sabiosciences.com/pcrarrayproto-
colfiles.php). These Ct values were then
normalized using 3 housekeeping genes
and proprietary software provided by the
manufacturer.25 Results were then
treated group-wise, and presented in clus-
ter-grams; with non-supervised hierarchi-
cal clustering of the entire dataset to
display a heat map with dendograms and
volcano plots.
Detection of influenza virus RNA in
tonsillar tissue
Detection of influenza virus RNA was
performed by running reverse transcrip-
tion and quantitative PCR, using specific
primers and probes on total RNA
extracted from tonsillar tissue samples.
We used validated reagents from BEI
resources (NIAD, NIH: Influenza Virus
Real-Time RT-PCR Assay, NR-15592)
and following the recommended proce-
dure. The kit enabled detection of A and
B viruses, as well as subtyping the A
viruses into H1, H3 and H5 strains.
Results
In this study we have vaccinated chil-
dren scheduled for elective tonsillectomy
Figure 2. Identifying gene clusters that are
involved in B and T cell activation. The col-
our gradient green-black-red represents rel-
ative level of gene expression, indicating
under-even-over expression, respectively.
The cluster gram shows a 2-way non-super-
vised hierarchical clustering of the entire
data set, while displaying a heat map with a
horizontal and vertical dendrogram indicat-
ing co-regulated genes across groups.
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with LAIV, and collected the tonsils for B and T cell gene array
analysis (Table 1). Samples were collected in an unvaccinated
control group (day 0) and at the operation day (variable days 3–
15 post LAIV). The subjects were divided into the following 4
groups: unvaccinated controls (n D 6), tonsillectomised 3–4 days
(group 1, n D 5), 6–7 days (group 2, n D 6), or 12–15 days
(group 3, n D 6) post 1st vaccine dose. Apart from suffering
from hypertrophic tonsils or recurrent tonsillitis, the patients
were healthy and fulfilled the criteria for vaccination. Only a few
patients had an increase in HI titer at the time of tonsillectomy
(Fig. 1).
Identifying gene clusters that are involved in B and T cell
activation
The dynamics of the locally induced B and T cell related gene
expression profiles were investigated in the tonsils at 3 different
times points following LAIV vaccination and compared to control
unvaccinated children. Total RNA was extracted from the tonsil-
lar tissue and a validated RT2 Profiler PCR Array analysis was
used to analyze gene expression profiles. The Ct values were gener-
ated individually for each subject and target gene. The samples
were then normalized using 3 housekeeping genes and the expres-
sion of 84 B and T cell specific genes (Tables S1 and S2) was stud-
ied by comparing the 3 post vaccination profiles with control
unvaccinated children. A qualitative analysis of the data was con-
ducted via cluster-grams, where genes within and across groups
showing similar numerical data are clustered together to display a
heat map with dendograms indicating co-regulated genes across
groups or individual samples. Compared to the controls, we iden-
tified one gene cluster that is under-expressed at days 3–4. We
observed an increased expression of genes on days 6–7, whereas
the majority of these genes were under-expressed in the control
group. However, at days 12–15 the number of under-expressed
genes decreased but remained above baseline levels (Fig. 2). The
dendograms in Figure 2 connect genes with similar numerical
expression. The vertical dendogram form 2 main bifurcations seg-
regating days 6–7 from the other time points. On the vertical den-
dogram, days 6–7 formed a cluster. Three clusters were observed
at days 6–7 compared to controls: Cluster A (IL10-SOC1 and
TNFSF14-VAV1), Cluster B (CD80-CD3G), and Cluster C
(CXCR4-CD40LG, AICDA-IFNg, CD3D-IL2RA and CD274-
IL18R1). Together, our observations suggest a marked under-
expression of genes on days 3–4. Whilst, 3 clusters of B and T cell
activated genes were identified on days 6–7.
T cell specific gene expression
T cell specific genes were classified into 6 different functional
categories, namely A) regulators of T cell activation, B) T cell
proliferation, C) T cell differentiation, D) T cell polarization, E)
regulators of Th1 and Th2 development, and F) Th1 and Th2
differentiation (Fig. 3). Genes involved in regulating T cell acti-
vation were downregulated at the earliest time point (3–4 days),
yet were overexpressed at days 6–7 (Fig. 3A), indicating an
increase in T cell activation. The levels of genes related to T cell
proliferation (Fig. 3B), T cell differentiation (Fig. 3C), and reg-
ulators of Th1/Th2 development (Fig. 3E) were relatively stably
over-expressed in the 3 vaccination groups compared to the con-
trols. The genes related to T cell polarization (Fig. 3D) and regu-
lator genes of Th1/Th2 differentiation (Fig. 3C), showed an
increased in expression levels at days 3–4 compared to controls,
they peaked at days 6–7 and returned to baseline levels at days
12–15.
Figure 3. T cell speciﬁc gene expression. T cell speciﬁc genes were classi-
ﬁed into 6 different categories (A) regulators of T cell activation, (B) T cell
proliferation, (C) T cell differentiation, (D) T cell polarization, (E) regula-
tors of Th1 and Th2 development, and (F) Th1 and Th2 differentiation, as
indicated above each plot. Each symbol represents the mean expression
level (C/¡ range) of T cell speciﬁc genes compared to controls. The
groups 1 to 3 are described in the text. The vertical scale indicates
whether these genes are up- or downregulated, where positive values
on the y-axis represent an up-regulation of genes, and negative values
represent a down-regulation.
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B cell specific gene expression
Genes involved in B cell activation were classified into 4 main
groups, specifically A) antigen-dependent B cell activation, B) B
cell proliferation, C) B cell differentiation and D) other genes
involved in B cell activation. Fold change values for all the genes
at each time point were plotted together and compared to the
controls (Fig. 4). At 3–4 days post vaccination, we observed that
genes involved in antigen-dependent B cell activation were
under-expressed compared to the controls, but were overex-
pressed at days 6–7 (Fig. 4A). Levels of B cell proliferation and
differentiation genes were higher on days 3–4 and 6–7, yet
became under-expressed at 12–15 days post vaccination
(Fig. 4B, C). Other genes involved in B cell activation were
under expressed in all groups compared to controls, yet to a lesser
extent at days 6–7 compared to days 3–4 and 12–15 post vacci-
nation (Fig. 4D).
The expression of other immune cell related genes
We investigated the expression of genes related to macro-
phage, neutrophil, natural killer cells and leukocyte activity
(Fig. 5). The activation of macrophage-specific genes increased
over time, and were highest at days 12–15 (Fig. 5A), while neu-
trophil-specific genes peaked at days 6–7 (Fig. 5B). Interestingly,
natural killer cell activation genes were under-expressed at days
6–7, and then became highly over-expressed at days 12–15
(Fig. 5C). Meanwhile, leukocyte-specific genes are under-
expressed in all 3 groups compared to controls, most highly
under-expressed at days 6–7 (Fig. 5D).
Significantly overexpressed genes and their contribution to
tonsillar immune functions
The genes that were significantly expressed and their overall
contribution to immune functions in the tonsils following LAIV
were shown in the Q1 & Q2 regions of the volcano plots
(Fig. 6). All 84 genes were almost equally distributed on both
sides of the volcano plot at 3–4 day post vaccination (Fig. 6A).
Compared to controls, the expression of CD3G, TLR1, FASLG,
APC, IL7 and CD8A located in the Q1 region were under-
expressed by up to 3 fold. Meanwhile, RIPK2 was significantly
Figure 4. B cell speciﬁc gene expression. Genes involved in B cell activa-
tion were classiﬁed into 4 main groups, speciﬁcally (A) antigen-depen-
dent B cell activation, (B) B cell proliferation, (C) B cell differentiation and
(D) other genes involved in B cell activation. Fold change values for all
the genes combined at each time point were plotted and compared to
the controls. Each symbol represents the mean level (C/¡ range) of B
cell speciﬁc gene expression. The vertical scale indicates fold change of
gene expression.
Figure 5. The expression of other immune cell related genes. Genes
involved in the activation of other immune cells include (A) macrophage
activation, (B) neutrophil activation, (C) natural killer cell activation, and
(D) leukocyte activation. Each plot represents the relative expression of
the respective combined cell speciﬁc gene in the test groups compared
to controls. The symbols indicate the mean gene expression level for the
3 groups (x-axis), and the range is indicated with vertical lines. The y-axis
represents the fold change in gene expression levels.
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Figure 6. For ﬁgure legend, see page 1669
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overexpressed, thereby located in the Q2 region. Hence,
as RIPK2 drives T cell proliferation the majority of these
down-regulated genes reduce B and T cell activation at 3–4 days
post vaccination. At 6–7 days after vaccination approximately
74% of the genes occupied the Q2 & Q4 regions of the plot
with 26% in Q3 and leaving Q1 empty (Fig. 6B). These overex-
pressed genes included IL8, MS4A1, IL2, PTPRC, SOCS1,
TGFB1, RIPK2, IL2RA, MICB. Overall, we found that many B
and T cell activation related genes including the aforementioned
genes were upregulated 6–7 days post vaccination. A decrease
occurred at days 12–15 (Fig. 6C), signifying the contraction of
the immune response and re-establishment of homeostasis. Here,
62 % of the entire gene set remained overexpressed compared to
the controls. These significantly overexpressed genes included
RIPK2, TLR2, IL4 and IL12B. Overall the contributions of these
genes promoted B and T cell activation.
No Influenza virus RNA was detected in the tonsillar tissue
We tested for the presence of viral RNA in total RNA extracts
from tonsillar tissue by using a validated real-time PCR assay
using influenza specific primers and probes. No influenza specific
RNA was detected in any of the samples using primers and
probes against influenza A and B viruses as well as H1, H3 and
H5 subtypes (data not shown).
Discussion
The tonsils are important in protection of the upper airways
against respiratory pathogens such as influenza. This virus is
major respiratory infection with up to 20% of children infected
annually. LAIV is preferentially recommended for influenza pro-
phylaxis in children in the UK, yet the mechanisms of immuno-
logical protection have not yet been defined. In this unique
pediatric clinical trial, we have vaccinated children at various
time intervals prior to elective tonsillectomy. We collected the
tonsils at the time of operation and isolated high quality RNA to
evaluate the dynamics of the B and T cell gene responses.
Recently, we reported the systemic effect of the LAIV vaccine in
a larger cohort including the children in the present study.21 We
found that LAIV elicited elevated B and T cell responses in these
young children, persisting for 1 year after vaccination, with the
highest responses observed against the B strain and the lowest to
the Influenza A H1N1 strain. Our study has a high number of
young children and is particularly unique in the collection of ton-
sils after vaccination allowing us to evaluate the local immune
response in the upper airways.
In this study, we have performed a gene expression analysis
with the goal of investigating the dynamics of B and T cell activa-
tion in tonsillar tissue following LAIV in children scheduled for
elective tonsillectomy, in order to identify possible prognostic
factors. Apart from fulfilling the criteria for tonsillectomy, our
patients were otherwise healthy, showing no signs of immune
compromise, as shown by stable immunoglobulin levels.20
Hence, the fold change gene values derived from our analysis
enable the investigation of the immunological processes in the
upper respiratory tract after LAIV. Our main finding is that at 6–
7 days post vaccination critical changes occur in gene expression
patterns which are probably fundamental for development of vac-
cine induced immunity (Fig. 2).
The LAIV contains cold adapted vaccine viruses capable of
limited replication in the upper respiratory tract. We were not
able to detect influenza virus RNA in the tonsillar tissue samples,
suggesting that the influenza virus antigen is taken up by den-
dritic cells in the nasal mucosa where the viruses replicate
(Fig. 7). The viral antigen may be carried by the activated den-
dritic cells, to local lymphoid tissue such as the tonsils, where the
viral antigen is presented to T cells.
Pivotal studies have recently focused on the importance of
pre-existing CD4 and CD8 T cells in protection from influenza
illness when neutralizing antibodies are absent.26 Wilkinson et al.
reported that pre-existing influenza specific CD4 T cells correlate
with disease protection in a human challenge model, with lower
levels of viral shedding and reduced severity of illness.27 Further-
more, protection from the 2009 pandemic H1N1 virus was
observed in individuals who had cross-reactive CD8 T cells to
the conserved internal proteins of the virus but no detectable neu-
tralizing antibodies.28,29 In our current study, we observed a peak
in the expression of genes involved in T cell differentiation, acti-
vation, polarization, and the regulation of Th1 and Th2 differen-
tiation on days 6–7 post LAIV immunization, suggesting an
induction of T lymphocyte commitment (Fig. 3). The commit-
ment to the different T helper subsets is presently characterized
by the expression of signature cytokines,30 where we found that
on days 6–7, increases in the expression of IL2 and IFN-g were
observed (Fig. 6B). LAIV induced significant increases in Th1
cells secreting IFN-g and IL-2 after the second dose of vaccine in
these children.21 Furthermore, these Th1 cells also secreted
TNF-a, which was not included in the gene array in this study
and should be studied in future trials. Influenza infection induces
secretion of large amounts of IFN-g, TNF-a and IL2, thereby
promoting the Th1 pathway.31,32 IL-2 is a central cytokine with
a number of key roles in development of influenza immunity,
where the IL-2 production from memory cells correlates to anti-
body levels.33,34 Furthermore, the expression of IL-2 and IL-2RA
Figure 6 (See previous page). Volcano plots of individual genes (dots) that are under and overexpressed compared to baseline (Controls). The horizon-
tal axis indicates the relative level of expression with a vertical line dividing the under expressed genes to the left (green) and over expresses to the right
(red). The y-axis indicates the statistical level of the change in gene expression with a horizontal line indicating the threshold (P-value < 0.05), and genes
situated above the line are denoted signiﬁcant using the student t-test. (A) gene expression in Group 1 (3–4 days post vaccination) compared to controls.
The green (left, n D 45) and red (right, n D 39) dots represent the under and overexpressed genes respectively. (B) gene expression in Group 2 (6–7 days
post-vaccination). The red (left, nD 62) and green (right, nD 22) dots represent genes that are over and under expressed respectively. (C) The genes that
are over expressed (red, n D 52) and under expressed (green, n D 32) 12–15 days following vaccination compared to controls.
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on days 6–7 indicates recent T cell activation, as the kinetics of
IL-2 is highest within the first 24 hours of infection.12,35 Mean-
while, there was a significant increase in IL-4 expression at days
12–15 (Fig. 6C). Since IL-4 is a key Th2 promoting cyto-
kine,32,36 our results suggest that LAIV is capable of inducing a
mixed Th1/Th2 cytokine response. A study by Woods et al.,37
with subjects inoculated with live influenza A (H1N1 or H3N2 )
virus found prominent change in interferon gene expression in
the blood at 3–4 days post. Whereas in our study of live attenu-
ated influenza viruses the greatest difference was found at 6–
7 days post vaccination.
Overall, we found that the T cell dependent B cell activation
and B cell differentiation initiated on days 3–4 increased up to
days 6–7, where reactions like antibody isotype switching, affinity
maturation and induction of J chain gene occur in the germinal
center, and may be responsible for the slight decline in B cell pro-
liferation (Fig. 4). Moreover, our data shows an increase in TGF-
b on days 6–7. TGF-b is involved in isotype switching to
IgA,38,39 a process that occurs extensively in the germinal centers
of the tonsils13 (Fig. 6B). It is also involved in regulating anti-
inflammatory processes. Hence, the increase in the secretion of
TGF-b on days 6–7 suggests isotype switching from IgM to IgA.
The subsequent secretion of IL4 on days 12–15 suggests that
there may be subsequent B cell differentiation (Fig. 6C).
In previous studies we have vaccinated adults with parenteral
TIV. The systemic effect was detectable after 4–5 days post TIV
vaccination with a peak in influenza specific antibody secreting
cells (ASC) after one week, and a peak in serum antibodies after
2 weeks.40 After TIV, mucosal antibodies appeared after 4–
5 days post vaccination with a peak in influenza specific tonsillar
ASC and salivary antibodies after one week.41,42 We have also
found a higher presence of influenza specific ASC in nasal tissue
than in blood or tonsils, but this was not influenced by vaccina-
tion.43,44 Parenteral vaccination also induced changes in cellular
pattern of the tonsils.45 Meanwhile, the LAIV vaccine elicits both
systemic responses21 as well as local mucosal immune responses
(data to be published).
When accounting for the involvement of other immune cells
(Fig. 5), we see an increase in macrophage activation throughout
all 3 time points. This is consistent with current findings
Figure 7. A suggested working model for LAIV. Upon vaccination with LAIV by intranasal droplets (1), limited virus replication of the vaccine strains may
occur in the nasal epithelial lining (2). Since we were not able to detect viral RNA in the tonsillar tissue, this indicates that viral antigens are transported
to the tonsils by activated DCs (3) and not through local vaccine virus replication. We observed in this study that B and T cells are activated by changes
in gene expression proﬁles, which are most pronounced at days 6–7 post vaccination (4, 5). An efﬂux of activated lymphocytes that may migrate to the
site of infection/vaccination (6) as is supported by an earlier study.45 Systemic and mucosal responses (7) were detected in these subjects after LAIV vac-
cination [21 and unpublished data].
1670 Volume 11 Issue 7Human Vaccines & Immunotherapeutics
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ite
tsb
ibl
iot
ek
et 
i B
erg
en
] a
t 0
4:3
6 2
1 D
ec
em
be
r 2
01
5 
suggesting that monocytes migrate to the site of infection,
become activated and perform phagocytosis and present antigen.
Neutrophils, on the other hand, migrate to the sites of infection,
as shown by the increase in IL-8 expression on days 6–7 and
phagocytose antigens (Fig. 6B). The increase in NK cells at days
6–7 suggests these cells perform cytotoxic functions and assist the
functions of effector B cells.
There may be several principal reasons for the observed
changes in gene expression profiles in the tonsils; vaccination
may induce activation, proliferation, influx/efflux of cells or a
combination of these. Further studies have to be performed to
reveal the exact mechanism behind the changes in the gene
expression profile.
A very prominent enzyme gene was overexpressed at all time
points in our study, namely RIPK2 (Fig. 6). The RIPK2 gene
encodes a protein kinase that is an important activator of the
NF-kB pathway and is implicated in the induction of apopto-
sis.46,47 The function of RIPK2 in apoptosis has previously been
tested in vitro, demonstrating that RIPK2 plays an important
role in the transduction of Fas-FasL induced apoptosis (extrinsic
pathway).48 Moreover, RIPK2 has been shown to protect against
severe influenza A virus infection by regulating the expression of
IFN-g and IL-18.48 IL-18 over-expression is thought to cause
increased morbidity and mortality in RIPK2 deficient mice by
hyperactivating lymphocyte induced inflammation. In bacterial
infections, RIPK2 plays an important role in activating the
Nucleotide-binding Oligomerisation Domain 2 (NOD2) to
induce autophagy; a cell stress-response induced in times of star-
vation and adaptation to limited resources in the milieu.49
Hence, in our study the involvement of RIPK2 in B and T cell
activation may be associated with the activation of transduction
factor NFkB, which is involved in the expression of many genes
including IL-2 (Fig. 6).
Conclusions
In conclusion, we have managed to gain a deeper understand-
ing of the gene expression processes following LAIV immunisa-
tion. Our data suggests an overall proliferation, differentiation
and regulation of B & T cells in the tonsils. Particularly, days 6–
7 highlights important dynamic gene expression patterns that are
probably fundamental for the development of vaccine induced
immunity. Some of the more interesting and significantly upre-
gulated genes were RIPK2, IL-2 and IL2-RA. Further studies are
needed to explore the more detailed roles of RIPK2 in influenza
infection, its involvement in severe inflammation reduction, viral
clearance and cytokine expression patterns in tonsillar tissues.
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